Impax Laboratories — Conference Presentation (January 2016)
18 slides from Impax Laboratories's conference presentation, Jan 12, 2016
Slide 1: Conference, January 12, 2016
onference ary 12, 2016
Slide 2: Impax Cautionary Statement Regarding Forward Looking Statements
Impax Cautionary Statement Regarding Forward Looking Statements fl pen aeah nectar emins, cea ear ane agate Patera Cig EL fae SoaisPicee en colin rice rng Vache tyne peau sds aa ‘consumer acceptance and demand for new pharmaceutical products; the impact of market perceptions of the Company and the s
Slide 3: Well-Positioned for Future Growth
Well-Positioned for Future Growth Investment Considerations Targeting Sustainable Generic pipeline of 46 products targeting $19B U.S. sales* Generic and Specialty pipeline focused on next generation opportunities Specialty Solid platform on which to build long-term growth Pharma Markets y Establishe
Slide 4: Dual Platforms for Growth
Dual Platforms for Growth Impax Generics Impax Specialty Pharma Targeting complex solid oral and alternative dosage form ANDAs with high revenue potential Developing products for unmet needs in the treatment of Central Nervous System disorders and other select specialty segments Product Portfolio 60
Slide 5: Strategy to Create Long Term Growth
Strategy to Create Long Term Growth L Focus on Quality and Operations + Maximize Dual Platform i Inga}
Slide 6: 1. Focusing on Quality and Operations
1. Focusing on Quality and Operations Delivered Positive Quality / Compliance Results in 2015 Corporate Quali + Continued to enhance structure and personnel + Ongoing focus on Quality Improvement Programs and Systems Facilities Middlesex + Five generic products approved in 2015 Hayward + Resolved Wa
Slide 7: 2. Maximizing Generic Platform
2. Maximizing Generic Platform Achieved 2015 Goal of Launching 14 Products 2015 Approvals and Launches J Products Approval 14 11 = Approvals Launches Data as ofDec, 24, 2015 FF = Fatto Fle Launch Lamotrigine ODT (Lamictal®) - FTF 1015 2016 ‘Azolastine Nasal (Astepro®) Relaunch 2016 Olopatadine Nasal
Slide 8: 2. Maximizing Generic Platform: Potential 2016 Launches
2. Maximizing Generic Platform Targeting Up to 16 Potential Launches in 2016 ‘otential Launches Targeted 28 Pending ANDAs at FDA 2016 Disclosed Pending ANDAs Include’: Mixed Amphetamine Salts ER capsule (Adderall XR®) Current U.S. Brand/Generic market sales of $5.68 Sevelamer Carbonate IR tablet (Re
Slide 9: 2. Maximizing Specialty Pharma Platform: RYTARY Launch
2. Maximizing Specialty Pharma Platform Successfully Launched RYTARY® in 2015 * Growth tracking to long range plan + 82% of all Rx’s have been Payer approved * 2% share of carbidopa/ levodopa segment Monthly TRx and Share of National CDLD TRx Since Launch 40,000 24% 2.1% 8,000 a8 6,000 ie 1.2% 4,000
Slide 10: 2. Maximizing Specialty Pharma Platform: Nasal Triptan Growth
2. Maximizing Specialty Pharma Platform Significant Growth Since Initiating Promotional Activity in 2Q 2012 Nasal Triptan TRx Growth Nasal Spray _National Segment enes Product Prescription Share Impax Apr. 2012 | Nov. 2015| Promotion Zomig® 23% 33% 83% Imitrex® 5% T% 15% gSumatriptan 72% 60% 2% Tota
Slide 11: Expanding and Internalizing Sales Force in 2016
2. Maximizing Specialty Pharma Platform Expanding and Internalizing Sales Force in 2016 # of CNS Sales Reps Approximately 120 7 66 2014 2015 2016 Promoting V Vv v V v + Builds scale to support organic growth + Provides increased geographic reach and frequency * Strong interest in RYTARY® results in
Slide 12: 2016 RYTARY Tactical Plan
2. Maximizing Specialty Pharma Platform 2016 RYTARY® Tactical Plan Choose RYTARY® Sales force expansion HCP campaign and amplification Improve Patient Experience Optimize Access Patient advocacy education Patient Support Service Center Sample direction kit Coverage Support Service Center Payer contr
Slide 13: 3. Optimizing Generic R&D
3. Optimizing Generic R&D Multiple Product Opportunities to Drive Future Growth Abbreviated New Drug Applications (ANDAs) 28 Products Pending at FDA 18 Products Under Development Current U.S. Brand/Generic Market - $9B Current U.S. Brand/Generic Market - $108 29% Potential/Confirmed FTF or FTM 50% P
Slide 14: 3. Optimizing Specialty Pharma R&D
3. Optimizing Specialty Pharma R&D Refocused Pipeline on Next Generation / Late-Stage Opportunities = Received European Commission Marketing Authorization Nov. 2015 NUMIENT™ = 28member states of European Union, as well as Iceland, Liechtenstein and Norway (IPXO66/RYTARY® * Centralized procedure subm
Slide 15: 4. Accelerating Business Development
4. Accelerating Business Development Achieved BD Acceleration and Improved Capital Structure in 2015 Completed Acq ion of Tower Holdings* * Compelling strategic and financial benefits + Provided a portfolio of growing, high-margin, complex products > Specialty products including Albenza® > Generic p
Slide 16: 4. Targeting Strategic Value Creating Opportunities
4. Accelerating Business Development Targeting Strategic Value Creating Opportunities Generic Specialty Pharma + Commercialized, Phase III or Phase Ill ready assets + Companies offering complex solid oral dosage forms with more sustainable margins + CNS: focused on movement + Alternative dosage form
Slide 17: 2016 Priorities
2016 Priorities I= * Maintain quality and compliance across all facilities / departments + Sharpen focus on supply chain and costefficiencies + Capture identified Tower acquisition synergies of $10 milion for 2016 + Improve conversion costs across global manufacturing network Maximize Dual Platform
Slide 18: Well-Positioned for Future Growth
Well-Positioned for Future Growth Investment Considerations Targeting Sustainable Generic pipeline of 46 products targeting $19B U.S. sales* Generic and Specialty pipeline focused on next generation opportunities Specialty Solid platform on which to build long-term growth Pharma Markets y Establishe
Impax Laboratories — Conference Presentation (January 2016) on 6ix